Non-Toxic Gel to Treat Vulvovaginal Candidiasis

用于治疗外阴阴道念珠菌病的无毒凝胶

• 批准号: 7051865
• 负责人: Charles J Gauntt
• 金额: $ 11.03万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7051865
• 关键词: Candida; candidiasis; gel; iodine

DESCRIPTION (provided by applicant): The goal of this project is to develop a safe biocidal vaginal gel for treatment of vulvovaginal candidiasis (WC). WC is caused by one of several airborne species of the yeast Candida that are normal inhabitants of humans at several sites, including the vagina. C. albicans has been associated with causing WC in the past, but drug-resistant non-C. albicans spp. are increasingly being identified as the cause of WC. Many of: he non-C. albicans strains are resistant to normal levels of antifungal drugs. As a result, recurrent WC has become an increasingly common and chronic problem, with patients becoming refractory to treatment due to imitations in available therapy. Biomedical Development Corporation (BDC) is evaluating lova gel as a novel, safe, and effective microbicide. lova gel is a broad-spectrum biocide with activity against viruses, bacteria, and yeast, without nducing resistant mutants or allergenicity. The goal of this project is to develop lova vaginal gel as a treatment for vulvovaginal candidiasis. BDC will execute the following specific aims: Specific Aim 1: Formulate lova Gel Formulations for Use in Treating Vulvovaginal Candidiasis Specific Aim 2: Demonstrate Safety of lova Gel Formulations Specific Aim 3: Demonstrate Effectiveness of lova Gel Formulations in Killing Planktonic Candida spp. Specific Aim 4: Demonstrate that lova Gel is Effective in Eradicating a Persistent Candida albicans Vaginal Infection in Rats , Relevance to Public Health: Vaginitis is the most common gynecologic diagnosis in primary care globally, affecting an estimated 1 billion women each year. WC accounts for 30-45% of vaginitis, and approximately 75% of premenopausal women will have at least one episode of WC. Among premenopausal women, 70- 75% will have at least one episode of WC and half of all college women will, by age 25, have had one episode of WC diagnosed by a physician. Annual costs for treating WC in the U.S. are estimated at $1.8 billion.

描述（由申请人提供）：该项目的目标是开发一种安全的阴道生物杀灭凝胶，用于治疗外阴阴道念珠菌病（WC）。WC是由几种空气传播的念珠菌中的一种引起的，念珠菌是人类几个部位的正常居民，包括阴道。过去，白色念珠菌与引起WC有关，但耐药的非c。白念珠菌越来越多地被认为是导致WC的原因。解析：选c。白色念珠菌菌株对正常水平的抗真菌药物具有耐药性。因此，复发性WC已成为一种越来越常见的慢性问题，由于现有治疗方法的限制，患者对治疗变得难治性。生物医学发展公司（BDC）正在评估卵细胞凝胶作为一种新型、安全、有效的杀微生物剂。Lova凝胶是一种广谱杀菌剂，对病毒、细菌和酵母菌具有活性，不会产生耐药突变体或致敏性。本项目的目标是开发用于治疗外阴阴道念珠菌病的阴道凝胶。BDC将执行以下具体目标：具体目标1：制定用于治疗外阴阴道念珠菌病的卵黄凝胶配方具体目标2：证明卵黄凝胶配方的安全性具体目标3：证明卵黄凝胶配方在杀死浮游念珠菌方面的有效性具体目标4：证明卵黄凝胶有效根除与公共卫生相关的大鼠持续性白色念珠菌阴道感染阴道炎是全球初级保健中最常见的妇科诊断，每年影响约10亿妇女。WC占阴道炎的30-45%，大约75%的绝经前妇女至少有一次WC发作。在绝经前的女性中，70- 75%的人至少会有一次WC发作，一半的大学女性在25岁之前会有一次被医生诊断为WC发作。在美国，每年治疗WC的费用估计为18亿美元。